This is the authors' abstract. We don't add key points for this paper.
Alzheimer disease (AD) predominantly affects individuals above 60 years of age. Autosomal dominant mutations in 3 genes— amyloid precursor protein (APP ), presenilin1 ( PSEN1 ), and presenilin2 ( PSEN2 )—account for a small proportion of AD cases. These cases are usually associated with an early age at onset (as early as the third decade, but have been shown to have onset as late as 70 years).1 Mutations in PSEN1 are more common (over 170 different mutations reported) than APP or PSEN2 mutations (http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=0&Page=Home). We have identified a family of Irish/English ancestry with a 2-generation history of autosomal dominant early onset AD (EOAD, onset in the late 40s). Affected individuals in this family carry a novel PSEN1 mutation, G217R. We describe the clinical features, autopsy findings, and biologic significance of this mutation. ### Case report. #### Clinical data. The proband was identified after referral to a clinical trial at age 54 years with symptom onset in her early 40s. She was unable to complete the clinical trial and was lost to follow-up. The pedigree was later referred to our center due to the strong family history of EOAD and a mutation identified in the proband (IV-4) by Athena Diagnostics. Eight people were reported by family history (figure, A) or medical records to have EOAD. The mean age at onset in this family is 45.5 years (range 43–47 years). The mean age at death is 55.5 years (range 49–65 years). The son of IV-10 contacted us at the time of his father’s death. By history and medical records, IV-10 had probable AD. At age 44 years, he was having anxiety attacks and depression. By age 46 years, he was unable to perform a …
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Norton et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: